Hormone Therapy for Lung Cancer Bellerose NY

Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

Local Companies

Sound Shore Medical Center
914-632-5000
16 Guion Place
New Rochelle, NY
Queens Hospital Center
718-883-3000
82-68 164th Street
Jamaica, NY
Mercy Medical Center
516-705-2525
1000 North Village Avenue
Rockville Centre, NY
Libertyhealth-Jersey City Ctr
201-915-2000
355 Grand Street
Jersey City, NJ
Brooklyn Hospital Center
718-250-8000
121 Dekalb Avenue
Brooklyn, NY
Burke Rehabilitation Hospital
914-597-2500
785 Mamaroneck Avenue
White Plains, NY
Queens Children'S Psych Center
718-264-4506
74-03 Commonwealth Boulevard
Jamaica, NY
Forest Hills Hospital
718-830-4000
102-01 66th Road
Forest Hills, NY
Lenox Hill Hospital
212-434-2000
100 East 77th Street
New York, NY
St Vincent'S Midtown Hospital
212-459-8000
415 West 51st Street
New York, NY
Data Provided by:
  

Provided By:

SATURDAY, Sept. 19 (HealthDay News) -- Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found.

The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

After eight years, 73 women taking the hormone therapy and 40 women in the placebo group had died of lung cancer. That meant, according to the researchers, that women who took the drug were 71 percent more likely to die from the disease.

The study also found that women taking the hormone therapy were 28 percent more likely to be diagnosed with lung cancer, although the study noted that the finding was not statistically significant.

"Treatment with estrogen plus progestin in postmenopausal women ... increased the number of deaths from lung cancer, in particular deaths from non-small-cell lung cancer," concluded Rowan Chlebowski, of the Los Angeles Biomedical Research Institute at Harbour-UCLA Medical Center, and his colleagues.

The researchers urged that the findings "be incorporated into risk-benefit discussions with women considering combined hormone therapy, especially those with a high risk of lung cancer ... such as current smokers or long-term past smokers."

Dr. Apar Kishor Ganti, from the University of Nebraska Medical Center in Omaha, wrote in an accompanying editorial that "because the optimum safe duration of hormone-replacement therapy in terms of lung cancer survival is unclear, such therapy should probably be avoided in women at a high risk of developing lung cancer, especially those with a history of smoking."

In fact, Ganti questioned whether hormone therapy should be used at all.

"These results, along with the findings showing no protection against coronary heart disease, seriously question whether hormone-replacement therapy has any role in medicine today," he wrote. "It is difficult to presume that the benefits of routine use of such therapy for menopausal symptoms outweigh the increased risks of mortality, especially in the absence of improvement in the quality of life."

The study, which appears online and in an upcoming print issue of The Lancet, was released Sept. 19 to coincide with the European Cancer Organization meeting.

More information

The U.S. National Institute on Aging has more on hormones and menopause.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Head and Neck Cancer Treatment Bellerose NY
Incomplete and interrupted radiation treatment is a common problem among Medicare patients with head and neck cancer, a new study has found. Researchers analyzed data from 5,086 Medicare patients diagnosed with head and neck cancer between 1997 and 2003 and found that nearly 40 percent of them experienced interruptions in radiation therapy or failed to complete the course of therapy.
- Drug Combo Proves Powerful Against Lung Cancer Bellerose NY
- Hormone Therapy Bellerose NY
- Menopausal Hormone Therapy Bellerose NY
- Hormone Therapy for Early Prostate Cancer Bellerose NY
- Hormone Therapy for Prostate Cancer Bellerose NY
- Breast Cancer Treatment Bellerose NY
- Delayed Prostate Cancer Therapy Bellerose NY
- Hormone Therapy for Breast Cancer Bellerose NY